| ¿µ¹® | Rorschach Test | ÇÑ±Û | ·Î¸£»þÇÏ °Ë»ç |
|---|---|---|---|
| ¼³¸í | »ç°íÀå¾Ö¿Í Á¤¼Àå¾Ö¿¡ ¹Î°¨ÇÑ Åõ»ç°Ë»ç(projective test). °ËÀº»ö°ú ¸î°¡Áö »öÀ¸·Î ÀÌ·ç¾îÁø À×Å©¾ó·è°°Àº µµÇüÀÌ ±×·ÁÁø 10°³ÀÇ Ä«µå¸¦ ÀÌ¿ëÇÑ´Ù. ÇǰËÀÚ¿¡°Ô Ä«µå¸¦ º¸ÀÌ°í º» °Í¿¡ ´ëÇØ ¸»Çϵµ·Ï ÇÑ´Ù. ´ÙÀ½¿¡´Â ¾ó·èÀÇ ¾î´À À§Ä¡°¡ ÇǰËÀÚ°¡ ¸»ÇÑ Áö°¢´ë»óÀ» ¾Ï½ÃÇÏ´ÂÁö ãµµ·Ï ÇÑ´Ù. ÇǰËÀÚÀÇ ´äº¯À» ºÐ¼®ÇÏ¸é ±×ÀÇ »ç°í¿Í Á¤¼»óÅ¿¡ ´ëÇÑ Á¤º¸¸¦ ¾òÀ» ¼ö ÀÖ´Ù. |
||
| ¿µ¹® | Mantoux test | ÇÑ±Û | ¸ÁÅä¿ì°Ë»ç |
|---|---|---|---|
| ¼³¸í | ¼Ò¾Æ¿¡ ÁÖ·Î ½Ç½ÃÇÏ´Â °Ë»ç ¹æ¹ýÀ¸·Î, BCGÁ¢Á¾ÈÄ¿¡³ª ȤÀº °áÇÙ±Õ¿¡ ÇѹøÀÌ¶óµµ ³ëÃâµÈ °æ¿ì¿¡ ¾ç¼º¹ÝÀÀÀ¸·Î ³ª¿Â´Ù. ¿ì¸®³ª¶ó¿¡¼´Â »ýÈÄ 1°³¿ù¿¡ BCG¿¹¹æÁ¢Á¾À» ½ÃÇàÇϹǷΠ´ëºÎºÐ ¾ç¼ºÀ¸·Î ³ª¿À°Ô µÇ³ª, ÀÌ ¿¹¹æÁ¢Á¾À» ¹ÞÁö ¾ÊÀº »óÅ¿¡¼ ¾ç¼ºÀ¸·Î ³ª¿À¸é, °áÇÙ±ÕÀÇ Ä§Åõ¸¦ ÀǽÉÇÒ ¼ö ÀÖ´Ù. |
||
| ¿µ¹® | stress test | ÇÑ±Û | ½ºÆ®·¹½º °Ë»ç |
|---|---|---|---|
| ¼³¸í | Çù½ÉÁõÀÌ ÀϾ±â ½¬¿î ȯÀÚ¿¡°Ô¼ ±× Á¤µµ¸¦ ÆÇ´ÜÇϱâÀ§ÇØ ½ÃÇàÇÑ´Ù. ¹æ¹ýÀº °°Àº °÷¿¡¼ ȯÀÚ¸¦ ´Þ¸®µµ·Ï ÇÑ ´ÙÀ½, ¾ó¸¶ÀÇ ¼Óµµ¿¡¼ Ç÷¾ÐÀÌ ¶³¾îÁö°í Çù½ÉÁõ Áõ»óÀÌ ³ªÅ¸³ª´Â°¡¸¦ °Ë»çÇÑ´Ù. ´ë°³ ½ÉÇÒ¼ö·Ï ³·Àº ¼Óµµ¿¡¼µµ Áõ»óÀÌ »¡¸® ³ªÅ¸³´Ù. |
||
| ¿µ¹® | visual field test | ÇÑ±Û | ½Ã¾ß°Ë»ç |
|---|---|---|---|
| ¼³¸í | ´«À» ÇѰ÷¿¡ °íÁ¤½ÃŲ ä, °üÂûÇÒ ¼ö ÀÖ´Â ÁÖº¯°ø°£À» ½Ã¾ß¶ó ÇÑ´Ù. ½Ã¾ß¸¦ °Ë»çÇÏ´Â °¡Àå °£´ÜÇÑ ¹æ¹ýÀº ´ë¸é°Ë»ç(confronting test)ÀÌ´Ù. À̰ÍÀº Çǰ˻çÀÚÀÇ ´«À» °Ë»çÀÚÀÇ ´«¿¡ ¸ÂÃß¾î º¸µµ·Ï ÇÏ¿© ´«À» °íÁ¤½ÃŲä, °Ë»çÀÚ°¡ ¼Õ°¡¶ô³¡À» À§ÂÊ, ¾Æ·¡ÂÊ, ¿ÞÂÊ, ¿À¸¥ÂÊ, ±×¸®°í ºñ½ºµëÈ÷ °æ»çÁø °÷ µîÀ¸·Î ¿Å°Üº¸¾Æ Çǰ˻çÀÚ°¡ °üÂûÇÒ ¼ö ÀÖ´ÂÁö ¿©ºÎ¸¦ Á¤ÇÏ´Â °Ë»ç¹ýÀÌ´Ù. À̺¸´Ù Á¤È®ÇÑ °Ë»ç¹ýÀº ÀÚµ¿½Ä ÄÄÇ»Åͽþ߰˻ç¹ýÀÌ ÀÖ´Ù. ´ë°³, ´«ÀÚüÀÇ ÀÌ»óÀÌ À־ ½Ã¾ß°Ë»ç¿¡¼ ÀÌ»óÀÌ ³ª¿ÀÁö¸¸, ÀÌ¿Ü ³úÀÇ ÀÌ»óÀ¸·Î ½Ã°¢ÀÇ Çü¼º°æ·Î¿¡ ÀÌ»óÀÌ À־ ¿ª½Ã ÀÌ»ó¼Ò°ßÀ» º¸ÀδÙ. |
||
| ¿µ¹® | Draw a person test | ÇÑ±Û | Àι°È ¼º°Ý°Ë»ç |
|---|---|---|---|
| ¼³¸í | Àι°È ¼º°Ý°Ë»ç´Â óÀ½¿¡´Â Áö´É°Ë»ç·Î °³¹ßµÇ¾ú°í, ±× ÈÄ¿¡´Â »ç¶÷ÀÇ ¹«ÀǽÄÀÇ ¿ä¼Ò¸¦ °Ë»çÇÏ´Â ¹æ¹ýÀ¸·Î ¹ßÀüÇÏ¿´´Ù. °Ë»çÀç·á´Â Áö¿ì°³°¡ ÀÖ´Â ¿¬Çʰú ¹éÁö¸¦ ÇǰËÀÚ¿¡°Ô ÁÖ°í, »ç¶÷À» ±×·Áº¸¶ó´Â Áö½Ã¸¦ Çϸç, °Ë»çÀÚ´Â ±×¸®´Â ¼ø¼¿Í Æò°¡¸¦ ±â·ÏÇϰí, ´Ù ±×¸° ÈÄ¿¡´Â ¸ÕÀú¿Í ´Ù¸¥ À̼ºÀ» ±×¸®µµ·Ï ÇÑ´Ù. ÀÌ °Ë»ç¿¡¼ÀÇ ½ÅüÀÇ ¸ð¾çÀº °ð ÀھƻóÀ» ¹Ý¿µÇÑ´Ù´Â ÀÔÀå, ±×¸²¿¡¼ °Á¶µÈ ±â°üÀº ÀÇ»ç¼ÒÅë¼ö´Ü, °ü³äÈ, ¿å±¸Ã¼°è, ¼ºÀû ´É·Â, °¥µî, ÁÂÀý°æÇè, ¼ºÀå·Â µîÀ» ¹Ý¿µÇÑ´Ù°í ÇÑ´Ù. À̰ÍÀº ¾Æµ¿°ú ¼ºÀο¡°Ô °³º°Àû ¶Ç´Â Áý´ÜÀûÀ¸·Î ½Ç½ÃÇÒ ¼ö ÀÖ°í, °£ÆíÇϸ鼵µ À¯ÀÍÇÑ °ÍÀÌ´Ù. ÀÓ»óÀûÀ¸·Î´Â ³úÀÇ ±âÁúÀû º¯È¸¦ ¾Ë¾Æ³»±â À§ÇÑ ¸ñÀûÀ¸·Îµµ ¸¹ÀÌ ÀÌ¿ëµÈ´Ù. |
||
| CAT | California Achievement Test; capillary agglutination test; catalase; cataract; catecholamine; Childr... |
|---|---|
| TAT | tetanus antitoxin; thematic apperception test; thematic aptitude test; thrombin-antithrombin complex... |
| BRA | bilateral renal agenesis; bone-resorbing activity; brain-reactive antibody |
| DRA | dextran-reactive antibody |
| PRA | panel-reactive antibody; phosphoribosylamine; physician recognition award; plasma renin activity; pr... |
| C-reactive protein | <protein> This blood test is used as an indicator of acute inflammation. C-reactive protein is a protein of the pentraxin family, produced by the liver during periods of inflammation and detectable in serum in various disease conditions particularly during the acute phase of immune response. Normally C-reactive protein should be negative in the bloodstream. C-reactive protein is synthesised by hepatocytes and its production may be triggered by prostaglandin E1 or parogen. It consists of five polypeptide sub units forming a molecule of total molecular weight 105 kD. It binds to polysaccharides present in a wide range of bacterial, fungal and other cell walls or cell surfaces and to lecithin and to phosphoryl or choline containing molecules. It is related in structure to Serum Amyloid. And C polysaccharide. Conditions which can cause a positive C-reactive protein include: rheumatoid arthritis, lupus, pneumococcal pneumonia, rheumatic fever, cancer, tuberculosis and myocardial infarction. A positive C-reactive protein may also be seen in the later half of pregnancy and in some who are taking birth control pills. See: acute phase proteins (06 Oct 1997) |
|---|---|
| thiobarbituric acid reactive substances | Low-molecular-weight end products, probably malondialdehyde, that are formed during the decomposition of lipid peroxidation products. These compounds react with thiobarbituric acid to form a fluorescent red adduct. (12 Dec 1998) |
| antibody-coated bacteria test, urinary | Fluorescent antibody technique for visualizing antibody-bacteria complexes in urine. The presence or absence of antibody-coated bacteria in urine correlates with localization of urinary tract infection in the kidney or bladder, respectively. (12 Dec 1998) |
| cytotropic antibody test | A rosette test for macrophage cytotropic antibody: monolayers of macrophages are exposed first to antibody cytotropic for macrophages, then to the antigen (for which the antibody is specific), and indicator sheep erythrocytes; if the antibody is specific for sheep erythrocytes, the latter will form a rosette around the macrophages directly, but if not, and the antigen is soluble, the antigen must be coupled to the sheep erythrocytes by an agent such as bis-diazotised benzidine. (05 Mar 2000) |
| direct fluorescent antibody test | Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (fluorescent antibody technique, direct) or an indirect method, by formation of antigen-antibody complex which is then labelled with fluorescein-conjugated anti-immunoglobulin antibody (fluorescent antibody technique, indirect). The tissue is then examined by fluorescence microscopy. (12 Dec 1998) |
| fluorescent antinuclear antibody test | FANA test, a test for antinuclear antibody components; used, in particular, for the diagnosis of collagen-vascular diseases. (05 Mar 2000) |
| fluorescent treponemal antibody-absorption test | <investigation> A sensitive and specific serologic test for syphilis. It is more specific than the VDRL assay. The patient's serum is diluted to remove non-specific antibodies and then mixed on a glass slide with Nichol's strain of Treponema pallidum. If antibodies are present in the patient's serum they bind to the antigen and the bound antibodies are detected with fluoresceinated antihuman gamma-globulin antibody. Synonym: FTA-ABS test. (12 Sep2002) |
| affinity antibody | The measure of the interaction between molecules such as a receptor and its ligand. This interaction is reversible. (05 Mar 2000) |
| agglutinating antibody | 1. An antibody that causes clumping or agglutination of the bacteria or other cells which either stimulated the formation of the agglutinin, or contain immunologically similar, reactive antigen. Synonym: agglutinating antibody, immune agglutinin. 2. A substance, other than a specific agglutinating antibody, that causes organic particles to agglutinate, commonly qualified, e.g., plant agglutinin. (05 Mar 2000) |
| anaphylactic antibody | Antibody that has an affinity for certain kinds of cells, in addition to and unrelated to its specific affinity for the antigen that induced it, because of the properties of the Fc portion of the heavy chain. See: heterocytotropic antibody, homocytotropic antibody, cytotropic antibody test. Synonym: anaphylactic antibody, cytophilic antibody. (05 Mar 2000) |
| anti-basement membrane antibody | Autoantibodies to renal glomerular basement membrane antigens. (05 Mar 2000) |
| antibody | An immunoglobulin molecule that has a specific amino acid sequence by virtue of which it interacts only with the antigen that induced its synthesis in cells of the lymphoid series (especially plasma cells) or with antigen closely related to it. Antibodies are classified according to their ode of action as agglutinins, bacteriolysins, haemolysins, opsonins, precipitins, etc. (18 Nov 1997) |
| antibody affinity | A measure of the binding strength between antibody and a simple hapten or antigen determinant. It depends on the closeness of stereochemical fit between antibody combining sites and antigen determinants, on the size of the area of contact between them, and on the distribution of charged and hydrophobic groups. It includes the concept of "avidity," which refers to the strength of the antigen-antibody bond after formation of reversible complexes. (12 Dec 1998) |
| antibody aldolase | <enzyme> Prepared by reactive immuninization to catalyze a wide variety of aldol reactions and decarboxylations Registry number: EC 4.1.2.- Synonym: fab 33f12, aldolase catalytic antibody (26 Jun 1999) |
| antibody combining site | <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope). Also used of the site on a ligand molecule to which a cell surface receptor binds. (18 Nov 1997) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|